Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640213 | 0.86 | UTS2R (0.35) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL19640210 | 0.81 | NPC1 (0.40) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL19640185 | 0.80 | KDM4E (0.41) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL19640193 | 0.78 | KDM4E (0.35) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL21331704 | 0.77 | MAOA (0.42) | KDM4EL3MBTL1POLBNPC1RAB9A | |
| SCHEMBL19643071 | 0.76 | UTS2R (0.41) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL19640186 | 0.75 | L3MBTL1 (0.44) | KDM4EL3MBTL1POLBNPC1RAB9A | |
| SCHEMBL21331685 | 0.74 | KDM4E (0.43) | KDM4EL3MBTL1POLBNPC1RAB9A | |
| SCHEMBL19663376 | 0.73 | L3MBTL1 (0.39) | UTS2RKDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL19642808 | 0.73 | UTS2R (0.39) | UTS2RKDM4EL3MBTL1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100052-B2 | — | — | 2018-10-16 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100052-B2 | — | HAVCR2, PYGL, FABP1 | UTS2R 3336/4885KDM4E 4413/4885L3MBTL1 3651/4885 |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | UTS2R 3013/4885KDM4E 4217/4885L3MBTL1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.